Tandem upgraded, Insulet downgraded at Stifel on market for tubeless insulin pumps
Stifel upgraded Tandem Diabetes Care (TNDM) to Buy and downgraded Insulet (PODD) to Hold, based on survey results about the tubeless insulin pump market.
INSULET CORP
Insulet develops, manufactures and sells continuous insulin delivery systems for people with insulin-dependent diabetes. Its Omnipod platform includes Omnipod 5, an automated insulin delivery system; Omnipod DASH, an insulin management system; and Classic Omnipod, which Insulet is phasing out. The tubeless, wearable Pod delivers insulin, and Omnipod 5 can integrate with third-party continuous glucose monitors. Insulet also produces pods for Amgen’s Neulasta Onpro kit. It provides data management services through Glooko and its Omnipod Discover analytics and reporting platform. Insulet sells Omnipod products through wholesalers, distribution partners and directly to consumers. In the United States, sales are primarily through wholesalers, with products generally covered by commercial insurance or government healthcare programs. International sales are direct to consumers or through distributors and intermediaries. Omnipod products are available in 25 countries. Insulet is headquartered in Acton, Massachusetts.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $PODD in the last 30 days.
See all $PODD insider activity →Stifel upgraded Tandem Diabetes Care (TNDM) to Buy and downgraded Insulet (PODD) to Hold, based on survey results about the tubeless insulin pump market.
Jefferies reiterated a Buy rating and $200 price target for Insulet (PODD), citing strong fundamentals and competitive advantages. The stock is down 56% over a year but is seen as undervalued. Insulet reported Q3 2026 sales of $842M, up 19.6%, and EPS of $1.99, up 60%. Analysts have mixed views on its outlook.
Stifel downgraded Insulet (PODD) to Hold from Buy, lowering its price target to $165 from $180 due to U.S. momentum concerns and competitive pressures. The stock has fallen 49% YTD. Despite this, Insulet's Q3 2026 earnings beat estimates, with revenue up 19.2% to $842M. Other analysts raised price targets post-earnings.
Over the past 7 days, AlphAI's AI scored 6 news stories mentioning PODD (INSULET CORP). Coverage has skewed bearish: 1 bullish, 1 neutral, and 4 bearish.
Recent PODD coverage spans financial news and earnings.
Downgrade bias likely weighs on PODD sentiment as investors reassess near-term competitive positioning implied by the survey.
Analyst rating upgrade and higher price target may support upside momentum.
The downgrade signals weaker outlook and may trigger sell pressure.
Watch PODD’s customer-base growth and retention trends into the next earnings print, as they are framed as the key driver of any large upside move.
Truist Securities kept Insulet at Hold but raised its price target to $160 from $153, a 4.6% increase. This implies a 9.2% upside from the Nov 6 close of $146.51. Recent analyst targets for Insulet range from $165 to $171.
AlphAI scores every news story that mentions PODD with an AI model for sentiment and relevance, and aggregates insider trades from INSULET CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.
Stifel upgraded Tandem Diabetes Care (TNDM) to Buy and downgraded Insulet (PODD) to Hold, based on survey results about the tubeless insulin pump market.
Jefferies reiterated a Buy rating and $200 price target for Insulet (PODD), citing strong fundamentals and competitive advantages. The stock is down 56% over a year but is seen as undervalued. Insulet reported Q3 2026 sales of $842M, up 19.6%, and EPS of $1.99, up 60%. Analysts have mixed views on its outlook.
Stifel downgraded Insulet (PODD) to Hold from Buy, lowering its price target to $165 from $180 due to U.S. momentum concerns and competitive pressures. The stock has fallen 49% YTD. Despite this, Insulet's Q3 2026 earnings beat estimates, with revenue up 19.2% to $842M. Other analysts raised price targets post-earnings.
Insulet (PODD) stock has historically seen large swings, with an 80% chance of a 50% jump in a given year. Its customer base grew over 20% in Q3 2026, driving a 19.2% revenue increase to $842 million. However, management expects slower growth in 2027. The stock trades at 3.3x sales and 24.7x earnings, with a $400 million buyback plan. Growth depends on customer retention and new product launches.
Truist Securities kept Insulet at Hold but raised its price target to $160 from $153, a 4.6% increase. This implies a 9.2% upside from the Nov 6 close of $146.51. Recent analyst targets for Insulet range from $165 to $171.
Barclays kept Insulet at Equal-Weight but raised its price target to $165 from $150, suggesting a 5.7% upside from the Nov 5 close of $156.12. Recent analyst notes on Insulet have price targets ranging from $167 to $180.
UBS kept its Neutral rating on Insulet but increased its price target to $171 from $150, suggesting a 9.5% upside from the last close. Recent analyst targets range from $167 to $200.
JP Morgan kept Insulet at Neutral but raised its price target to $170 from $152, suggesting an 8.9% upside from the Nov 5 close. Recent analyst targets range from $167 to $200.
Leerink Partners kept Insulet at Market Perform, raising its price target to $167 from $143, a 16.8% increase. This implies 1.2% upside from the Nov 4 close of $165.02. Recent analyst targets for Insulet range from $150 to $200.
RBC Capital maintained its Outperform rating on Insulet and raised its price target to $180 from $160, citing a 9.1% upside from the Nov 4 close of $165.02. Recent analyst price targets for Insulet range from $150 to $200.